News Channels

07 Dec 2017 Evolve BioSystems' Activated B. infantis EVC001 Demonstrates Substantial and Persistent Remodeling of the Infant Gut Microbiome
07 Dec 2017 Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)
07 Dec 2017 Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
07 Dec 2017 Carmot Enters a Multi-Year Drug Discovery Collaboration With Amgen
07 Dec 2017 Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
07 Dec 2017 Phase III IMpower150 Study Showed Tecentriq (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Reduced the Risk of Disease Worsening or Death by 38 Percent for People with a Type of Advanced Lung Cancer
07 Dec 2017 Chugai’s Emicizumab Every Four Weeks Showed Positive Interim Results in Phase III Study
07 Dec 2017 BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
07 Dec 2017 GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
06 Dec 2017 Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
06 Dec 2017 Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
06 Dec 2017 TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1
06 Dec 2017 Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
06 Dec 2017 Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
06 Dec 2017 Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
06 Dec 2017 Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy
06 Dec 2017 Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products
06 Dec 2017 Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer
06 Dec 2017 New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
06 Dec 2017 DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top